You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the VERQUVO (vericiguat) Drug Profile, 2024 PDF Report in the Report Store ~

VERQUVO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Verquvo, and when can generic versions of Verquvo launch?

Verquvo is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are six patents protecting this drug.

This drug has two hundred and ten patent family members in forty-nine countries.

The generic ingredient in VERQUVO is vericiguat. One supplier is listed for this compound. Additional details are available on the vericiguat profile page.

DrugPatentWatch® Generic Entry Outlook for Verquvo

Verquvo will be eligible for patent challenges on January 19, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 26, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for VERQUVO
International Patents:210
US Patents:6
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 52
Clinical Trials: 2
Patent Applications: 153
Drug Prices: Drug price information for VERQUVO
What excipients (inactive ingredients) are in VERQUVO?VERQUVO excipients list
DailyMed Link:VERQUVO at DailyMed
Drug patent expirations by year for VERQUVO
Drug Prices for VERQUVO

See drug prices for VERQUVO

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VERQUVO
Generic Entry Date for VERQUVO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VERQUVO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme LLCPhase 2
Johns Hopkins UniversityPhase 2
Merck Sharp & Dohme LLCPhase 4

See all VERQUVO clinical trials

Pharmacology for VERQUVO

US Patents and Regulatory Information for VERQUVO

VERQUVO is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VERQUVO is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VERQUVO


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Substituted 5-fluoro-1H-pyrazolopyridines and their use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

Substituted 5-flouro-1H-pyrazolopyridines and their use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%

FDA Regulatory Exclusivity protecting VERQUVO

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-003 Jan 19, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck Sharp Dohme VERQUVO vericiguat TABLET;ORAL 214377-001 Jan 19, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VERQUVO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bayer AG Verquvo vericiguat EMEA/H/C/005319
Treatment of symptomatic chronic heart failure
Authorised no no no 2021-07-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for VERQUVO

When does loss-of-exclusivity occur for VERQUVO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Patent: 98
Estimated Expiration: ⤷  Try a Trial

Argentina

Patent: 8983
Estimated Expiration: ⤷  Try a Trial

Patent: 5027
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 12342547
Estimated Expiration: ⤷  Try a Trial

Patent: 17254916
Estimated Expiration: ⤷  Try a Trial

Patent: 19202123
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2014012414
Estimated Expiration: ⤷  Try a Trial

Patent: 2020001312
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 56706
Estimated Expiration: ⤷  Try a Trial

Patent: 40720
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 14001339
Estimated Expiration: ⤷  Try a Trial

Patent: 16000344
Estimated Expiration: ⤷  Try a Trial

China

Patent: 4159898
Estimated Expiration: ⤷  Try a Trial

Patent: 5503867
Estimated Expiration: ⤷  Try a Trial

Patent: 6905314
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 60555
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 140237
Estimated Expiration: ⤷  Try a Trial

Patent: 190057
Estimated Expiration: ⤷  Try a Trial

Patent: 210072
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0161501
Estimated Expiration: ⤷  Try a Trial

Patent: 0181818
Estimated Expiration: ⤷  Try a Trial

Patent: 0210507
Estimated Expiration: ⤷  Try a Trial

Cuba

Patent: 257
Estimated Expiration: ⤷  Try a Trial

Patent: 354
Estimated Expiration: ⤷  Try a Trial

Patent: 140055
Estimated Expiration: ⤷  Try a Trial

Patent: 150123
Estimated Expiration: ⤷  Try a Trial

Patent: 150124
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 24000
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 82914
Estimated Expiration: ⤷  Try a Trial

Patent: 96617
Estimated Expiration: ⤷  Try a Trial

Patent: 21470
Estimated Expiration: ⤷  Try a Trial

Dominican Republic

Patent: 014000112
Estimated Expiration: ⤷  Try a Trial

Patent: 017000013
Estimated Expiration: ⤷  Try a Trial

Patent: 021000179
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 14001627
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 0018
Estimated Expiration: ⤷  Try a Trial

Patent: 1602
Estimated Expiration: ⤷  Try a Trial

Patent: 3455
Estimated Expiration: ⤷  Try a Trial

Patent: 1491028
Estimated Expiration: ⤷  Try a Trial

Patent: 1690520
Estimated Expiration: ⤷  Try a Trial

Patent: 1690521
Estimated Expiration: ⤷  Try a Trial

Patent: 1892050
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 82914
Estimated Expiration: ⤷  Try a Trial

Patent: 96617
Estimated Expiration: ⤷  Try a Trial

Patent: 21470
Patent: 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUÉES SOUS FORME CRISTALLINE (SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES IN CRYSTALLINE FORM)
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 1400101
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 03951
Estimated Expiration: ⤷  Try a Trial

Patent: 23613
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 31029
Estimated Expiration: ⤷  Try a Trial

Patent: 41592
Estimated Expiration: ⤷  Try a Trial

Patent: 53745
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 6265
Estimated Expiration: ⤷  Try a Trial

Patent: 3389
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 89315
Estimated Expiration: ⤷  Try a Trial

Patent: 40391
Estimated Expiration: ⤷  Try a Trial

Patent: 92436
Estimated Expiration: ⤷  Try a Trial

Patent: 15502932
Estimated Expiration: ⤷  Try a Trial

Patent: 17031180
Estimated Expiration: ⤷  Try a Trial

Patent: 18058860
Estimated Expiration: ⤷  Try a Trial

Patent: 18199698
Estimated Expiration: ⤷  Try a Trial

Jordan

Patent: 0120351
Estimated Expiration: ⤷  Try a Trial

Patent: 0210064
Estimated Expiration: ⤷  Try a Trial

Patent: 0210065
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 82914
Estimated Expiration: ⤷  Try a Trial

Patent: 96617
Estimated Expiration: ⤷  Try a Trial

Patent: 21470
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 8412
Estimated Expiration: ⤷  Try a Trial

Patent: 7904
Estimated Expiration: ⤷  Try a Trial

Patent: 8086
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 7481
Estimated Expiration: ⤷  Try a Trial

Patent: 14006018
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 718
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 4593
Estimated Expiration: ⤷  Try a Trial

Patent: 1592
Estimated Expiration: ⤷  Try a Trial

Patent: 4215
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 142359
Estimated Expiration: ⤷  Try a Trial

Patent: 190180
Estimated Expiration: ⤷  Try a Trial

Patent: 190181
Estimated Expiration: ⤷  Try a Trial

Philippines

Patent: 014501160
Estimated Expiration: ⤷  Try a Trial

Patent: 015501494
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 82914
Estimated Expiration: ⤷  Try a Trial

Patent: 96617
Estimated Expiration: ⤷  Try a Trial

Patent: 21470
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 82914
Estimated Expiration: ⤷  Try a Trial

Patent: 96617
Estimated Expiration: ⤷  Try a Trial

Patent: 21470
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 387
Estimated Expiration: ⤷  Try a Trial

Patent: 945
Estimated Expiration: ⤷  Try a Trial

Patent: 609
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 201604192X
Estimated Expiration: ⤷  Try a Trial

Patent: 201604196V
Estimated Expiration: ⤷  Try a Trial

Patent: 201402111Q
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 82914
Estimated Expiration: ⤷  Try a Trial

Patent: 96617
Estimated Expiration: ⤷  Try a Trial

Patent: 21470
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1403613
Estimated Expiration: ⤷  Try a Trial

Patent: 1505970
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1943788
Estimated Expiration: ⤷  Try a Trial

Patent: 1993022
Estimated Expiration: ⤷  Try a Trial

Patent: 2026059
Estimated Expiration: ⤷  Try a Trial

Patent: 140105483
Estimated Expiration: ⤷  Try a Trial

Patent: 170130612
Estimated Expiration: ⤷  Try a Trial

Patent: 190018021
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 03028
Estimated Expiration: ⤷  Try a Trial

Patent: 94158
Estimated Expiration: ⤷  Try a Trial

Patent: 64009
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 97280
Estimated Expiration: ⤷  Try a Trial

Patent: 31123
Estimated Expiration: ⤷  Try a Trial

Patent: 59016
Estimated Expiration: ⤷  Try a Trial

Patent: 65198
Estimated Expiration: ⤷  Try a Trial

Patent: 1329076
Estimated Expiration: ⤷  Try a Trial

Patent: 1708219
Estimated Expiration: ⤷  Try a Trial

Patent: 1831447
Estimated Expiration: ⤷  Try a Trial

Patent: 1838993
Estimated Expiration: ⤷  Try a Trial

Patent: 1932465
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 14000227
Estimated Expiration: ⤷  Try a Trial

Turkey

Patent: 1816203
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 6623
Estimated Expiration: ⤷  Try a Trial

Patent: 9269
Estimated Expiration: ⤷  Try a Trial

Patent: 0278
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 467
Estimated Expiration: ⤷  Try a Trial

Patent: 646
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VERQUVO around the world.

Country Patent Number Title Estimated Expiration
Ukraine 109660 ЗАМІЩЕНІ 5-ФТОР-1H-ПІРАЗОЛОПІРИДИНИ ТА ЇХ ЗАСТОСУВАННЯ ⤷  Try a Trial
Dominican Republic P2012000299 5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS Y SU USO ⤷  Try a Trial
Croatia P20161501 ⤷  Try a Trial
Poland 2576547 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VERQUVO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2576547 2021C/553 Belgium ⤷  Try a Trial PRODUCT NAME: VERICIGUAT EN ZIJN ZOUTEN, SOLVATEN EN SOLVATEN VAN DE ZOUTEN; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720
2576547 LUC00221 Luxembourg ⤷  Try a Trial PRODUCT NAME: VERICIGUAT ET SES SELS, SOLVATES ET SOLVATES DES SELS; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720
2576547 CA 2021 00032 Denmark ⤷  Try a Trial PRODUCT NAME: VERICIGUAT OG DETS SALTE, SOLVATER OG SOLVATER AF SALTENE; REG. NO/DATE: EU/1/21/1561 20210720
2576547 301146 Netherlands ⤷  Try a Trial PRODUCT NAME: VERICIGUAT; REGISTRATION NO/DATE: EU/1/21/1561 20210720
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.